ALDH1L1-AS1

Across TCGA pan-cancer cohorts, ALDH1L1-AS1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ALDH1L1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ALDH1L1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ALDH1L1-AS1 is over-expressed in tumor, although a few such as BRCA and CHOL show the opposite, repressed pattern.

LIHC, BRCA, and CHOL are the cancer types where ALDH1L1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALDH1L1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	III,IV	+0.348	.007	5	view →
BRCA	All	II,III,IV	−0.100	<.001	4	view →
CHOL	Male	All	−0.425	.027	2	view →
THCA	All	All	−0.083	.009	2	view →
KIRC	Male	All	+0.078	.026	2	view →
PRAD	All	All	−0.072	.010	2	view →
KICH	Female	II,III,IV	−0.201	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ALDH1L1-AS1–LIHC

Open the LIHC breakdown →